Posted on

How your attachment style affects your trip

Psilocybin-assisted psychotherapy might help to reduce attachment anxiety

A new study suggests that psilocybin therapy can make patients feel more secure in their relationships!

After undergoing individual therapy, group therapy, and a single psilocybin session, a group of 18 male AIDS survivors showed significantly reduced scores for attachment anxiety – an attachment style characterized by clinginess, fear of abandonment, and difficulty trusting others.

There were no significant changes in attachment avoidance, which is characterized by repressing emotions and discomfort with close relationships.

However, high attachment anxiety scores were associated with a greater chance of mystical experiences, whereas high attachment avoidance scores were linked to grief, fear, physical distress, and paranoia during the trip.

PDF of article

PDF of study

Posted on

First-of-its-kind study on severe anxiety

World-first psilocybin clinical trial in the treatment of Generalised Anxiety Disorder receives ethics approval

This Australian university just got the go-ahead to conduct a first-of-its-kind study!

Yesterday, Monash University received ethics approval for a triple-blinded, active-placebo-controlled study that will investigate psilocybin-assisted psychotherapy as a treatment for severe Generalized Anxiety Disorder (GAD).

Researchers are looking to recruit 72 patients for the study, which will be conducted in partnership with Incannex Healthcare Ltd (IHL).

The therapists facilitating the study will have the option to undergo their own psilocybin session to better understand what the patients will experience.

PDF of article

Posted on

The future of psychedelics, according to an expert

Where the Psychedelic Revolution Is Headed, According to the Guy Who (Arguably) Started It

Rick Doblin, a pioneer psychedelic researcher and activist, made some interesting predictions about the future of psychedelics in the US.

Here’s where he thinks the sector is headed:

  • MDMA will be FDA-approved by the end of 2023, with psilocybin following a year or two after.
  • By 2023 or 2024, there will be 6000+ psychedelic therapy clinics (there are currently about 1000). Every town with a hospice center will have enough demand for a psychedelic clinic.
  • By 2030, one million MDMA therapy sessions will have been administered by 25,000 trained therapists.
  • A licensed legalization model could be implemented around 2035 in which patients can earn a license to use psychedelics outside the clinic once undergoing a supervised session.

Doblin is hopeful that the tremendous impacts on mental health will result in a spiritualized society that “has finally come to the point of embracing global thinking, global humanity, and dealt with economic inequity.”

PDF of article

Posted on

Which company will develop a dementia treatment first?

MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias

If treatments don’t improve, the number of Americans battling Alzheimer’s is expected to nearly triple by 2050, reaching $1.1 trillion in care costs.

Fortunately, two more companies joined the race to develop a new treatment using psychedelics!

On Tuesday, MYND Life Sciences (MYND) acquired IP rights from Cava Healthcare Inc. for dementia treatments using psilocybin and other psychedelics. It received the assets in exchange for 450,000 shares at $0.85 each, plus $120,000 and an annual royalty fee.

Silo Pharma Inc. (SILO) also joined the race this week through a sponsored research agreement. The company will work with Columbia University to develop a psychedelic treatment that could halt or reverse Alzheimer’s.

PDF of article 1

PDF of article 2

Posted on

A better way to get drunk?

Clearmind Signs Development and Supply Agreement to Produce its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences

This psychedelic makes you feel drunk. Could it be used to treat alcoholism?

5-Methoxy-2-aminoindane (MEAI) is a synthetic molecule that simulates the euphoric feeling of alcohol while reducing the desire to drink.

Pre-clinical studies conducted by Clearmind Medicine Inc. (CMND) show promising evidence that MEAI could treat alcohol use disorder (AUD) and binge drinking. Clinical trials expected to begin in the second half of 2022.

The company just signed a development and supply agreement with Aragen Life Sciences to manufacture the molecule.

PDF of article

Posted on

Group therapy cures depression in half of cancer patients!

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

On Tuesday, Compass Pathways (CMPS) received a US patent for COMP360, its proprietary formulation of crystalline psilocybin. On Wednesday, the company announced positive findings from an open-label study using the formulation to treat depression in cancer patients.

Thirty patients were administered COMP360 in group therapy sessions of two to four people. Twenty four people experienced at least a 50% reduction in depression symptoms within three weeks of treatment, which was sustained at week eight, and fifteen people were in total remission from depression. The average depression score dropped from 25.9 to just 6.8.

The company notes that the study was not blinded or placebo-controlled, so the findings are subject to expectancy bias, but the results show promise that both COMP360 and group therapy models are effective.

PDF of article 1

PDF of article 2

Posted on

Autistic children try microdosing

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

According to preclinical research conducted by Nova Mentis (NOVA), psilocybin has potential to reduce anxiety in autistic patients and could improve cognitive function in patients with fragile x syndrome (FXS), a genetic condition that causes learning impairments.

Now, the company is forming a joint venture with Mycrodose Therapeutics to accelerate R&D into the treatment. The partnership will use Mycrodose Therapeutics’ patented systems to self-administer a non-invasive microdose.

The joint venture plans to conduct human clinical trials on a broad range of patients with FXS and autism spectrum disorder (ASD), including pediatric patients. This will be the first study investigating psilocybin’s impact on children.

PDF of article

Posted on

Why your employer should let you do drugs

PSYCH: THE PSYCHEDELICS AS MEDICINE REPORT

Psych’s third annual report on psychedelic medicine revealed some interesting findings.

According to a survey of 440 healthcare professionals working in various fields, two thirds said they were excited about psychedelics as medicines. Of those who’ve personally tried the drugs for therapeutic or spiritual purposes, 83% were in favour of psychedelic medicine.

Consumers also showed a positive view of psychedelics, with about two thirds supporting medical legalization and 38% noting that someone they know would benefit from psychedelic therapy. When asked which psychedelic they would want to try in therapy, psilocybin and salvia were the most popular choices.

The report also showed that psychedelic therapy could save employers US$64 billion in Europe and US$270 billion in America due to fewer sick days and increased productivity.

PDF of report

Posted on

Is MDMA the Viagra for women?

LOVE PHARMA INC., ANNOUNCES LISTING ON FRANKFURT STOCK EXCHANGE

A Vancouver company called LOVE Pharma (LUV) wants to promote mental and sexual wellness with its growing product line.

The company recently launched two products (a CBD oral strip and a clitoral stimulation gel) and has exclusive rights to a total of seven novel therapeutic products. It’s currently developing a biosynthetic psilocybin strip using the IP from the CBD strip.

On Tuesday, the company was listed on  the Frankfurt Stock Exchange under the symbol “G1Q0”.

In other sexual wellness news, Mindcure (MCUR) recently launched a research program to treat female hypoactive sexual desire disorder (HSDD), a disorder involving low sex drive and emotional distress, with MDMA-assisted therapy.

PDF of article 1

PDF of article 2

Posted on

A trippy (family-friendly) vacay

Novamind Launches New Psychedelic Palliative Care Program

Patients in palliative care have higher rates of depression – could a psychedelic retreat change this?

Yesterday, Novamind (NM) launched a first-of-its-kind program to help both patients and their families cope with terminal illness.

The program, called “Psychedelic Palliative Care by Novamind”, combines psychedelic-assisted therapy with workshops, multi-day immersive retreats, and group support at its recently-opened clinic in Murray, Utah.

“Due to psychedelic medicine’s generally low side effect burden and fast-acting nature, it shows promise for patients who are physically ill and might have limited life expectancies,” said Novamind’s Chief Scientific Officer.

PDF of article